ImmunityBio Continues Trimming Workforce While Working to Advance Anktiva

ImmunityBio will part with 10 employees this quarter. Last fall, it cut 31 employees. The moves come as the biotech works to advance Anktiva in non-small cell lung cancer.

Scroll to Top